Rubiera Marta, Alvarez-Sabín José, Ribo Marc, Montaner Joan, Santamarina Esteban, Arenillas Juan F, Huertas Rafael, Delgado Pilar, Purroy Francisco, Molina Carlos A
Department of Neurology, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Spain.
Stroke. 2005 Jul;36(7):1452-6. doi: 10.1161/01.STR.0000170711.43405.81. Epub 2005 Jun 9.
We aimed to determine clinical and hemodynamic predictors of early reocclusion (RO) in stroke patients treated with intravenous tissue plasminogen activator (tPA).
We studied 142 consecutive stroke patients with a documented middle cerebral artery (MCA) occlusion treated with intravenous tPA. All patients underwent carotid ultrasound and transcranial Doppler (TCD) examination before tPA bolus. National Institutes of Health Stroke Scale (NIHSS) scores were performed at baseline and serially for <24 hours. TCD monitoring of MCA recanalization (RE) and RO was performed during the first 2 hours after tPA bolus and repeated when clinical deterioration occurred <24 hours after documented RE in absence of intracranial hemorrhage.
After 1 hour of tPA administration, RE occurred in 84 (61%) patients (53 partial, 31 complete). Of these, 21 (25%) patients worsened after an initial improvement and 17 (12%) of them showed RO on TCD. RO was identified at a mean time of 65+/-55 minutes after documented RE. RO was associated (P=0.034) with a lower degree of 24-hour NIHSS score improvement than sustained RE, and a higher modified Rankin scale score at 3 months (P=0.002). Age older than 75 years (P=0.012), previous antiplatelet treatment (P=0.048), baseline NIHSS score >16 points (P=0.009), higher leukocytes count (P=0.042), beginning of RE <60 minutes after tPA bolus (P=0.039), and ipsilateral severe carotid stenosis/occlusion (P=0.001) were significantly associated with RO. In a logistic regression model, NIHSS score >16 at baseline (odds ratio [OR], 7.1; 95% CI, 1.3 to 32) and severe ipsilateral carotid disease (OR, 13.3; 95% CI, 3.2 to 54) remained as independent predictors of RO.
Stroke severity and ipsilateral severe carotid artery disease independently predict RO after tPA-induced MCA RE.
我们旨在确定接受静脉注射组织型纤溶酶原激活剂(tPA)治疗的中风患者早期再闭塞(RO)的临床和血流动力学预测因素。
我们研究了142例连续的经记录证实为大脑中动脉(MCA)闭塞且接受静脉tPA治疗的中风患者。所有患者在推注tPA前均接受了颈动脉超声和经颅多普勒(TCD)检查。在基线时及之后<24小时内连续进行美国国立卫生研究院卒中量表(NIHSS)评分。在推注tPA后的最初2小时内对MCA再通(RE)和RO进行TCD监测,并且在记录到RE后<24小时且无颅内出血而临床病情恶化时重复监测。
给予tPA 1小时后,84例(61%)患者出现RE(53例部分再通,31例完全再通)。其中,21例(25%)患者在最初病情改善后病情恶化,其中17例(12%)在TCD上显示RO。RO在记录到RE后的平均时间为65±55分钟时被识别。与持续RE相比,RO与24小时NIHSS评分改善程度较低相关(P = 0.034),且与3个月时改良Rankin量表评分较高相关(P = 0.002)。年龄大于75岁(P = 0.012)、既往抗血小板治疗(P = 0.048)、基线NIHSS评分>16分(P = 0.009)、白细胞计数较高(P = 0.042)、推注tPA后<60分钟开始出现RE(P = 0.039)以及同侧严重颈动脉狭窄/闭塞(P = 0.001)与RO显著相关。在逻辑回归模型中,基线时NIHSS评分>16分(比值比[OR],7.1;95%可信区间[CI],1.3至32)和同侧严重颈动脉疾病(OR,13.3;95%CI,3.2至54)仍然是RO的独立预测因素。
中风严重程度和同侧严重颈动脉疾病独立预测tPA诱导的MCA RE后的RO。